文献速递银屑病与炎症性皮肤病

ABP 501与阿达木单抗单次转换后临床相似性:52周III期试验长期结果

Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long-term results from a randomized controlled, double-blind, 52-week, phase III trial in patients with moderate-to-severe plaque psoriasis.
PubMed 文献 · Br J Dermatol · 2017-12-01

这项随机双盲52周III期试验在中重度斑块状银屑病患者中比较ABP 501与阿达木单抗的临床相似性。第16周时,达到PASI 50改善的患者继续治疗至第52周,其中阿达木单抗组患者被重新随机分为继续阿达木单抗或单次转换至ABP 501。结果显示,各组在第16、32和50周的PASI改善百分比相似,安全性和免疫原性也相似。

要点

  • ABP 501与阿达木单抗在中重度斑块状银屑病中显示相似的疗效、安全性和免疫原性。
  • 单次从阿达木单抗转换至ABP 501后,52周内未发现新的安全性信号。

核心结论

  • ABP 501与阿达木单抗在52周内具有相似的临床疗效、安全性和免疫原性,包括单次转换后。

研究设计与样本

  • 随机、对照、双盲、52周III期试验,患者按1:1随机接受ABP 501或阿达木单抗40 mg每2周,第16周时PASI 50应答者继续至第52周,阿达木单抗组重新随机1:1继续阿达木单抗或单次转换至ABP 501。

主要发现

  • 第16周重新随机共308例患者:ABP 501/ABP 501组152例,阿达木单抗/阿达木单抗组79例,阿达木单抗/ABP 501组77例。
  • 受累体表面积百分比变化在各组和时间点相似,未检测到新的安全性信号,不良事件组间平衡。
  • 结合性和中和性抗药抗体百分比在各治疗组间相似。

关键数值与推荐

  • 第16周时,达到PASI 50改善的患者有资格继续治疗至第52周。
  • ABP 501或阿达木单抗40 mg每2周给药一次,持续16周。

临床怎么用

  • ABP 501可作为阿达木单抗的生物类似药用于中重度斑块状银屑病,单次转换后疗效和安全性相似。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: ABP 501, a U.S.A. Food and Drug Administration- and European Medicines Agency-approved biosimilar, is highly similar to adalimumab in structure, function and pharmacokinetics. OBJECTIVES: To demonstrate similarity in efficacy, safety and immunogenicity of ABP 501 vs. adalimumab for moderate-to-severe plaque psoriasis (clinical trial: NCT01970488). METHODS: Patients were randomized (1 : 1) to receive ABP 501 or adalimumab 40 mg every 2 weeks for 16 weeks. At week 16, patients with ≥ 50% improvement from baseline in Psoriasis Area and Severity Index (PASI) score were eligible to continue to week 52. Patients receiving ABP 501 continued; adalimumab patients were rerandomized (1 : 1) to continue adalimumab or undergo a single transition to ABP 501. Key efficacy assessments included percentage PASI improvement from baseline, PASI responders and mean change in affected body surface area from baseline to weeks 16, 32 and 50. Safety was monitored via adverse events (AEs) and antidrug antibodies (ADAs) were assessed. RESULTS: A total of 308 patients were rerandomized at week 16 (ABP 501/ABP 501, n = 152; adalimumab/adalimumab, n = 79; adalimumab/ABP 501, n = 77). PASI percentage improvements from baseline were similar across groups for weeks 16, 32 and 50 (range: 85·8-88·2%), with no significant differences detected across groups in percentages of PASI 50, 75, 90 and 100 responders. Changes from baseline in percentage body surface area affected were similar across groups and time points. No new safety signals were detected. AEs were balanced between groups. Percentages of patients with binding and neutralizing ADAs were similar across treatments. CONCLUSIONS: ABP 501 and adalimumab have similar clinical efficacy, safety and immunogenicity profiles over 52 weeks, including after single transition, in this patient population.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Papp K, Bachelez H, Costanzo A, et al. Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long-term results from a randomized controlled, double-blind, 52-week, phase III trial in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2017. PMID: 28755394. doi:10.1111/bjd.15857

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。